Based on their biological behavior in host, pathological grade and genotype of donor tumor, the Living Tumor Lines are divided into a number of characterized xenograft models. Each model can be subdivided according to their particular histopathological types.
Characterized cancer models at the Living Tumor Laboratory |
|
---|---|
Models |
Tumor type |
Low-grade cancer models |
Lung carcinoma, ovarian carcinoma, prostatic carcinoma, pancreatic carcinoma, renal carcinoma, sarcoma, lymphoma |
Slow growing models |
|
Invasive models |
|
Metastatic models |
|
Genomic/epigenetic Mutant/deletion models |
Ovarian carcinoma (e.g. BRCA1 mutant), Lung carcinoma (e.g. ## fusion). |
A number of paired sublines derived from cancer specimens from individual patients, but showing different biological behavior in host, are available. Such paired sublines provide unique models for studying tumor hetergeneity, specific mechanisms,discovering biomarkers, and developing new targeted anticancer drugs.
Paired sublines developed in the Living Tumor Laboratory |
|||
---|---|---|---|
Subline Type |
Subline origin |
Sublines |
Biological characteristics of sublines |
Paired metastatic / non-metastatic tumor tissue sublines |
Ovarian serous carcinoma |
LTL-297A |
No local tissue invasion, no metastasis in host |
LTL-297B |
Locally invasive, highly metastatic in host |
||
Prostatic adenocarcinoma |
LTL-64A |
Metastasis to distant organs in host |
|
LTL-64B |
No metastasis in host |
||
Prostatic adenocarcinoma |
LTL-220A |
Metastasis to distant organs in host |
|
LTL-220B |
No metastasis in host |
||
Pancreatic adenocarcinoma |
LTL-190A |
|
|
LTL-190B |
|
||
Paired androgen responsive / non-responsive tumor tissue sublines |
Prostatic adenocarcinoma |
LTL-64AR |
Androgen-stimulated tumor growth |
LTL-64AS |
Androgen-suppressed tumor growth |
||
LTL-64AI |
Androgen-independent tumor growth |
||
Paired fast growing / slow growing tumor tissue sublines |
Ovarian serous carcinoma |
LTL-247H |
Fast growing with 5-6 days doubling time under the renal capsule |
|
LTL-247S |
Slow growing with 13 days doubling time under the renal capsule |
Human lymphoma sublines |
||
---|---|---|
Parental tumor line |
Subline |
Biological characteristics of the sublines |
LTL-79 |
LTL-79/C13 |
10 cycles of CDDP+VP16 treatment. Tumor is resistant to the drug |
LTL-117 |
LTL-117/C6 |
6 cycles of CDDCP+VNB. Tumor is still response to the drug. |
LTL-175 |
LTL-175/C6 |
6 cycles of carboplatin and paclitaxol treatment. Tumor is still response to the drug. |
LTL-297B |
LTL-297B/C4 |
4 cycles of carboplatin and paclitaxol treatment. Tumor is resistant to the drug. |